Business
Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019
NEW YORK, May 30, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for
About this update from Nexttrip, Inc.
[{"type":"text","content":"NEW YORK, May 30, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Charles Ryan, CEO, will be a featured presenter at the LD Micro Invitational Conference on Tuesday, June 4, 2019 at 9:40 AM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. \nDr. Ryan will provide an overview of the Company's business model and growth strategy and will be available for one-on-one meetings.\nFor those interested in attending, or for registered attendees who wish to request meetings, please contact David Scher, via email, at [email protected] or visit www.ldmicro.com for more information.\nAbout Neurotrope\nNeurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.\nIn addition to the Company's Phase 2 trial of Bryostatin-1 in advanced AD, Neurotrope has also conducted preclinical studies of Bryostatin-1 as a potential treatment for rare diseases and brain injury, including Fragile X syndrome, multiple sclerosis, stroke, Niemann-Pick Type C disease, Rett syndrome, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.\nPlease visit www.neurotrope.com for further information.\nForward-Looking Statements\nAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successfu...